1
|
Masoumi KC, Huang X, Sime W, Mirkov A, Munksgaard Thorén M, Massoumi R, Lundgren-Åkerlund E. Integrin α10-Antibodies Reduce Glioblastoma Tumor Growth and Cell Migration. Cancers (Basel) 2021; 13:cancers13051184. [PMID: 33803359 PMCID: PMC7980568 DOI: 10.3390/cancers13051184] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/19/2021] [Revised: 03/02/2021] [Accepted: 03/05/2021] [Indexed: 01/08/2023] Open
Abstract
Simple Summary Glioblastoma (GB) is the most common and most deadly form of brain tumor in adults which currently lacks effective treatments. Thus, there is a high need to identify new and effective ways to target the aggressive GB cells and treat the GB patients. In this study, we investigated the treatment effect of two antibodies that have been developed to target the protein integrin α10β1, which is present on the surface of GB cells. Our results show that the growth of GB tumor cells is reduced in the presence of the α10β1 antibodies. The treatment effect is demonstrated both in cell experiments and in an animal model. In addition, we found that the antibodies reduce the migration of the GB cells. We suggest that function-blocking antibodies targeting the integrin α10β1 is a promising new approach to treat glioblastoma patients. Abstract Glioblastoma (GB) is the most common and the most aggressive form of brain tumor in adults, which currently lacks efficient treatment strategies. In this study, we investigated the therapeutic effect of function-blocking antibodies targeting integrin α10β1 on patient-derived-GB cell lines in vitro and in vivo. The in vitro studies demonstrated significant inhibiting effects of the integrin α10 antibodies on the adhesion, migration, proliferation, and sphere formation of GB cells. In a xenograft mouse model, the effect of the antibodies on tumor growth was investigated in luciferase-labeled and subcutaneously implanted GB cells. As demonstrated by in vivo imaging analysis and caliper measurements, the integrin α10-antibodies significantly suppressed GB tumor growth compared to control antibodies. Immunohistochemical analysis of the GB tumors showed lower expression of the proliferation marker Ki67 and an increased expression of cleaved caspase-3 after treatment with integrin α10 antibodies, further supporting a therapeutic effect. Our results suggest that function-blocking antibody targeting integrin α10β1 is a promising therapeutic strategy for the treatment of glioblastoma.
Collapse
Affiliation(s)
| | - Xiaoli Huang
- Xintela AB, Medicon Village, Scheeletorget 1, SE-223 81 Lund, Sweden; (K.C.M.); (X.H.); (A.M.); (M.M.T.)
| | - Wondossen Sime
- IVRS AB, Medicon Village, Scheeletorget 1, SE-223 81 Lund, Sweden; (W.S.); (R.M.)
| | - Anna Mirkov
- Xintela AB, Medicon Village, Scheeletorget 1, SE-223 81 Lund, Sweden; (K.C.M.); (X.H.); (A.M.); (M.M.T.)
| | - Matilda Munksgaard Thorén
- Xintela AB, Medicon Village, Scheeletorget 1, SE-223 81 Lund, Sweden; (K.C.M.); (X.H.); (A.M.); (M.M.T.)
| | - Ramin Massoumi
- IVRS AB, Medicon Village, Scheeletorget 1, SE-223 81 Lund, Sweden; (W.S.); (R.M.)
| | - Evy Lundgren-Åkerlund
- Xintela AB, Medicon Village, Scheeletorget 1, SE-223 81 Lund, Sweden; (K.C.M.); (X.H.); (A.M.); (M.M.T.)
- Correspondence: ; Tel.: +46-46-275-6500
| |
Collapse
|
2
|
Munksgaard Thorén M, Chmielarska Masoumi K, Krona C, Huang X, Kundu S, Schmidt L, Forsberg-Nilsson K, Floyd Keep M, Englund E, Nelander S, Holmqvist B, Lundgren-Åkerlund E. Integrin α10, a Novel Therapeutic Target in Glioblastoma, Regulates Cell Migration, Proliferation, and Survival. Cancers (Basel) 2019; 11:cancers11040587. [PMID: 31027305 PMCID: PMC6521287 DOI: 10.3390/cancers11040587] [Citation(s) in RCA: 28] [Impact Index Per Article: 5.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/22/2019] [Revised: 04/18/2019] [Accepted: 04/23/2019] [Indexed: 12/28/2022] Open
Abstract
New, effective treatment strategies for glioblastomas (GBMs), the most malignant and invasive brain tumors in adults, are highly needed. In this study, we investigated the potential of integrin α10β1 as a therapeutic target in GBMs. Expression levels and the role of integrin α10β1 were studied in patient-derived GBM tissues and cell lines. The effect of an antibody–drug conjugate (ADC), an integrin α10 antibody conjugated to saporin, on GBM cells and in a xenograft mouse model was studied. We found that integrin α10β1 was strongly expressed in both GBM tissues and cells, whereas morphologically unaffected brain tissues showed only minor expression. Partial or no overlap was seen with integrins α3, α6, and α7, known to be expressed in GBM. Further analysis of a subpopulation of GBM cells selected for high integrin α10 expression demonstrated increased proliferation and sphere formation. Additionally, siRNA-mediated knockdown of integrin α10 in GBM cells led to decreased migration and increased cell death. Furthermore, the ADC reduced viability and sphere formation of GBM cells and induced cell death both in vitro and in vivo. Our results demonstrate that integrin α10β1 has a functional role in GBM cells and is a novel, potential therapeutic target for the treatment of GBM.
Collapse
Affiliation(s)
| | | | - Cecilia Krona
- Department of Immunology, Genetics and Pathology, Science for Life Laboratory, Rudbeck Laboratory, Uppsala University, SE-751 85 Uppsala, Sweden.
| | - Xiaoli Huang
- Xintela AB, Medicon Village, SE-223 81 Lund, Sweden.
| | - Soumi Kundu
- Department of Immunology, Genetics and Pathology, Science for Life Laboratory, Rudbeck Laboratory, Uppsala University, SE-751 85 Uppsala, Sweden.
| | | | - Karin Forsberg-Nilsson
- Department of Immunology, Genetics and Pathology, Science for Life Laboratory, Rudbeck Laboratory, Uppsala University, SE-751 85 Uppsala, Sweden.
| | - Marcus Floyd Keep
- Department of Neurosurgery, Sanford Brain and Spine Institute, Fargo, ND 58103, USA; Department of Surgery, School of Medicine, University of North Dakota, Fargo, ND 58102, USA.
| | - Elisabet Englund
- Neuropathology Lab, Division of Oncology and Pathology, Department of Clinical Sciences, Lund University, SE-221 84 Lund, Sweden.
| | - Sven Nelander
- Department of Immunology, Genetics and Pathology, Science for Life Laboratory, Rudbeck Laboratory, Uppsala University, SE-751 85 Uppsala, Sweden.
| | - Bo Holmqvist
- ImaGene-iT AB, Medicon Village, SE-223 81 Lund, Sweden.
| | | |
Collapse
|
3
|
Munksgaard Thorén M, Vaapil M, Staaf J, Planck M, Johansson ME, Mohlin S, Påhlman S. Myc-induced glutaminolysis bypasses HIF-driven glycolysis in hypoxic small cell lung carcinoma cells. Oncotarget 2018; 8:48983-48995. [PMID: 28430666 PMCID: PMC5564742 DOI: 10.18632/oncotarget.16904] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/23/2016] [Accepted: 03/29/2017] [Indexed: 01/10/2023] Open
Abstract
We previously demonstrated that small cell lung carcinoma (SCLC) cells lack HIF-2α protein expression, whereas HIF-1α in these cells is expressed at both acute and prolonged hypoxia. Here we show that low HIF2A expression correlates with high expression of MYC genes. Knockdown of HIF1A expression had no or limited effect on cell survival and growth in vitro. Unexpectedly, hypoxic ATP levels were not affected by HIF-1α knockdown and SCLC cell viability did not decrease upon glucose deprivation. In line with these in vitro data, xenograft tumor-take and growth were not significantly affected by repressed HIF1A expression. Glutamine withdrawal drastically decreased SCLC cell proliferation and increased cell death at normoxia and hypoxia in a HIF-independent fashion and the dependence on glutaminolysis was linked to amplification of either MYC or MYCL. Downregulation of GLS expression, regulating the first step of the glutaminolysis pathway, in MYC/MYCL overexpressing SCLC cells resulted in both impaired growth and increased cell death. Our results suggest that MYC/MYCL overexpression in SCLC cells overrides the need of HIF-1 activity in response to hypoxia by inducing glutaminolysis and lipogenesis. Targeting the glutaminolysis pathway might hence be a novel approach to selectively kill MYC amplified SCLC cells in vivo.
Collapse
Affiliation(s)
- Matilda Munksgaard Thorén
- Translational Cancer Research, Department of Laboratory Medicine, Lund University, Medicon Village, Lund, Sweden
| | - Marica Vaapil
- Translational Cancer Research, Department of Laboratory Medicine, Lund University, Medicon Village, Lund, Sweden.,Current address: Biosciences Area, Division of Environmental Genomics and Systems Biology, Lawrence Berkeley National Laboratory, Berkeley, CA, USA
| | - Johan Staaf
- Division of Oncology and Pathology, Department of Clinical Sciences Lund, Lund University, Medicon Village, SE Lund, Sweden
| | - Maria Planck
- Division of Oncology and Pathology, Department of Clinical Sciences Lund, Lund University, Medicon Village, SE Lund, Sweden.,Department of Oncology, Skåne University Hospital, SE Lund, Sweden
| | - Martin E Johansson
- Center for Molecular Pathology, Department of Laboratory Medicine, Lund University, Skåne University Hospital, Malmö, Sweden
| | - Sofie Mohlin
- Translational Cancer Research, Department of Laboratory Medicine, Lund University, Medicon Village, Lund, Sweden
| | - Sven Påhlman
- Translational Cancer Research, Department of Laboratory Medicine, Lund University, Medicon Village, Lund, Sweden
| |
Collapse
|
4
|
Hamidian A, von Stedingk K, Munksgaard Thorén M, Mohlin S, Påhlman S. Differential regulation of HIF-1α and HIF-2α in neuroblastoma: Estrogen-related receptor alpha (ERRα) regulates HIF2A transcription and correlates to poor outcome. Biochem Biophys Res Commun 2015; 461:560-7. [PMID: 25912138 DOI: 10.1016/j.bbrc.2015.04.083] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/14/2015] [Accepted: 04/16/2015] [Indexed: 12/14/2022]
Abstract
Hypoxia-inducible factors (HIFs) are differentially regulated in tumor cells. While the current paradigm supports post-translational regulation of the HIF-α subunits, we recently showed that hypoxic HIF-2α is also transcriptionally regulated via insulin-like growth factor (IGF)-II in the childhood tumor neuroblastoma. Here, we demonstrate that transcriptional regulation of HIF-2α seems to be restricted to neural cell-derived tumors, while HIF-1α is canonically regulated at the post-translational level uniformly across different tumor forms. Enhanced expression of HIF2A mRNA at hypoxia is due to de novo transcription rather than increased mRNA stability, and chemical stabilization of the HIF-α proteins at oxygen-rich conditions unexpectedly leads to increased HIF2A transcription. The enhanced HIF2A levels do not seem to be dependent on active HIF-1. Using a transcriptome array approach, we identified members of the Peroxisome proliferator-activated receptor gamma coactivator (PGC)/Estrogen-related receptor (ERR) complex families as potential regulators of HIF2A. Knockdown or inhibition of one of the members, ERRα, leads to decreased expression of HIF2A, and high expression of the ERRα gene ESRRA correlates with poor overall and progression-free survival in a clinical neuroblastoma material consisting of 88 tumors. Thus, targeting of ERRα and pathways regulating transcriptional HIF-2α are promising therapeutic avenues in neuroblastoma.
Collapse
Affiliation(s)
- Arash Hamidian
- Lund University, Translational Cancer Research, Lund University Cancer Center at Medicon Village, Building 406, SE-223 81 Lund, Sweden
| | - Kristoffer von Stedingk
- Lund University, Translational Cancer Research, Lund University Cancer Center at Medicon Village, Building 406, SE-223 81 Lund, Sweden
| | - Matilda Munksgaard Thorén
- Lund University, Translational Cancer Research, Lund University Cancer Center at Medicon Village, Building 406, SE-223 81 Lund, Sweden
| | - Sofie Mohlin
- Lund University, Translational Cancer Research, Lund University Cancer Center at Medicon Village, Building 406, SE-223 81 Lund, Sweden
| | - Sven Påhlman
- Lund University, Translational Cancer Research, Lund University Cancer Center at Medicon Village, Building 406, SE-223 81 Lund, Sweden.
| |
Collapse
|
5
|
Summers DF, McElvain NF, Thorén MM, Levintow L. Incorporation of amino acids into polyribosome-associated protein in cytoplasmic extracts of poliovirus-infected HeLa cells. Biochem Biophys Res Commun 1964; 15:290-5. [PMID: 4158131 DOI: 10.1016/0006-291x(64)90162-7] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/09/2023]
|